Technology

Chiasma

$4.24
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.04 (+0.96%) Today
+$0.04 (+0.95%) As of 10:33 AM UTC after-hours

Why Robinhood?

You can buy or sell Chiasma and other stocks, options, and ETFs commission-free!

About CHMA

Chiasma, Inc. operates as a clinical-stage biopharmaceutical company, which engages in developing and commercializing oral forms of therapies that are available by injection. Its products include octreotide capsules and clinical trials. The firm's Transient Permeability Enhancer (TPE) technology platform, seeks to develop oral medications. The company was founded by Shmuel A. Ben-Sasson and Guy Yachin in 2001 and is headquartered in Waltham, MA. The listed name for CHMA is Chiasma, Inc. Common Stock.

CEO
Raj Kannan
Employees
48
Headquarters
Needham, Massachusetts
Founded
2001
Market Cap
232.27M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.61M
High Today
$4.24
Low Today
$4.09
Open Price
$4.19
Volume
1.53M
52 Week High
$7.75
52 Week Low
$2.88

Collections

CHMA Earnings

-$0.50
-$0.33
-$0.17
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 15, After Hours

You May Also Like

SLMBP
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure